Charles River Laboratories International Stock Price, News & Analysis (NYSE:CRL)

$102.43 0.92 (0.91 %)
(As of 11/21/2017 04:00 PM ET)
Previous Close$101.51
Today's Range$100.86 - $102.49
52-Week Range$69.51 - $119.05
Volume364,263 shs
Average Volume381,296 shs
Market Capitalization$4.80 billion
P/E Ratio19.92
Dividend YieldN/A
Beta0.94

About Charles River Laboratories International (NYSE:CRL)

Charles River Laboratories International logoCharles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Life Sciences Tools & Services
  • Sector: Healthcare
  • Symbol: NYSE:CRL
  • CUSIP: 15986410
  • Web: www.criver.com
Debt:
  • Debt-to-Equity Ratio: 1.13%
  • Current Ratio: 1.88%
  • Quick Ratio: 1.62%
Price-To-Earnings:
  • Trailing P/E Ratio: 19.92
  • Forward P/E Ratio: 19.97
  • P/E Growth: 1.62
Sales & Book Value:
  • Annual Sales: $1.68 billion
  • Price / Sales: 2.89
  • Cash Flow: $7.44 per share
  • Price / Cash: 13.77
  • Book Value: $17.73 per share
  • Price / Book: 5.78
Profitability:
  • Trailing EPS: $4.09
  • Net Income: $154.76 million
  • Net Margins: 10.72%
  • Return on Equity: 26.58%
  • Return on Assets: 8.92%
Misc:
  • Employees: 11,000
  • Outstanding Shares: 47,360,000
 

Frequently Asked Questions for Charles River Laboratories International (NYSE:CRL)

What is Charles River Laboratories International's stock symbol?

Charles River Laboratories International trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

How will Charles River Laboratories International's stock buyback program work?

Charles River Laboratories International announced that its board has approved a stock repurchase plan on Sunday, June 4th 2017, which allows the company to repurchase $150,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company's board of directors believes its shares are undervalued.

How were Charles River Laboratories International's earnings last quarter?

Charles River Laboratories International, Inc. (NYSE:CRL) released its earnings results on Thursday, November, 9th. The medical research company reported $1.30 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.22 by $0.08. The medical research company earned $464.23 million during the quarter, compared to the consensus estimate of $458.93 million. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. Charles River Laboratories International's revenue was up 9.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.18 EPS. View Charles River Laboratories International's Earnings History.

When will Charles River Laboratories International make its next earnings announcement?

Charles River Laboratories International is scheduled to release their next quarterly earnings announcement on Monday, February, 12th 2018. View Earnings Estimates for Charles River Laboratories International.

What guidance has Charles River Laboratories International issued on next quarter's earnings?

Charles River Laboratories International updated its FY17 earnings guidance on Thursday, November, 9th. The company provided earnings per share (EPS) guidance of $5.08-5.18 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.10. The company issued revenue guidance of $1.845-1.857 billion, compared to the consensus revenue estimate of $1.85 billion.

Where is Charles River Laboratories International's stock going? Where will Charles River Laboratories International's stock price be in 2017?

10 equities research analysts have issued 1 year price objectives for Charles River Laboratories International's stock. Their forecasts range from $77.00 to $130.00. On average, they anticipate Charles River Laboratories International's share price to reach $106.65 in the next twelve months. View Analyst Ratings for Charles River Laboratories International.

What are Wall Street analysts saying about Charles River Laboratories International stock?

Here are some recent quotes from research analysts about Charles River Laboratories International stock:

  • 1. According to Zacks Investment Research, "Charles River Laboratories is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. Charles River is the global leader in providing the animal research models required in research and development for new drugs, devices and therapies and has been in this business for more than 50 years. " (11/13/2017)
  • 2. UBS AG analysts commented, "CRL reported 4Q16 results with reported revenue of $467m, above both our estimate of $442m and consensus estimates of $441m. Adj. EPS of $1.21 was above both ours and consensus estimates of $1.11. Management guided to 7.5% ' 9% revenue growth (7% ' 8.5% org.) and adj. EPS of $5.00 - $5.10 for FY17. For 1Q17, reported revenue growth is expected in the mid-20% and adj. EPS growth of mid- to high-teens' Our Sell rating is based on the following: 1) We are becoming more selective in our CRO universe and CRL is primarily exposed to early development markets which we think are most at risk should biopharma markets slow. 2) We estimate that street forecasts for 2017 are too high and think CRL's multiple could revert to its mean should estimates need to come down as we anticipate. 3) We estimate that CRL is most at risk in our universe should interest rates begin to rise." (2/15/2017)
  • 3. Jefferies Group LLC analysts commented, "4Q results far outpaced consensus revenue/EPS driven by strength across the 3 segments. Guidance bracketed consensus, lower than us (as expected). We point to margin expansion (with continued price) and capital deployment as upside sources. Strong Discovery and Early Development demand (see our research pointing to funding shifts to Early Dev) should support high single digit organic growth." (2/15/2017)

Who are some of Charles River Laboratories International's key competitors?

Who are Charles River Laboratories International's key executives?

Charles River Laboratories International's management team includes the folowing people:

  • James C. Foster, Chairman of the Board, President, Chief Executive Officer (Age 66)
  • David R. Smith, Chief Financial Officer, Corporate Executive Vice President (Age 51)
  • David P. Johst, Corporate Executive Vice President - Human Resources, Chief Administrative Officer, General Counsel (Age 55)
  • William D. Barbo, Corporate Executive Vice President and Chief Commercial Officer (Age 56)
  • Davide A. Molho, Corporate Executive Vice President & President, Global Research Models & Services, Safety Assessment and Biologics (Age 47)
  • Michael Gunnar Knell, Corporate Senior Vice President, Chief Accounting Officer (Age 40)
  • George M. Milne Jr., Ph.D., Lead Independent Director (Age 73)
  • Martin Mackay Ph.D., Director (Age 60)
  • Robert J. Bertolini, Independent Director (Age 55)
  • Stephen D. Chubb, Independent Director (Age 73)

Who owns Charles River Laboratories International stock?

Charles River Laboratories International's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Mackenzie Financial Corp (1.96%), Bank of New York Mellon Corp (1.71%), Neuberger Berman Group LLC (1.66%), Brown Advisory Inc. (1.45%), Van Berkom & Associates Inc. (1.37%) and First Trust Advisors LP (1.16%). Company insiders that own Charles River Laboratories International stock include Bradley Nixon Scharfe, C Richard Reese, David P Johst, David Ross Smith, Davide Molho, George M Milne Jr, George Massaro, James C Foster, Jason Wesley Scharfe, John J Crowley, Nancy Gillett, Richard F Wallman, Robert J Bertolini, Stephen D Chubb, Thomas F Ackerman and William D Barbo. View Institutional Ownership Trends for Charles River Laboratories International.

Who sold Charles River Laboratories International stock? Who is selling Charles River Laboratories International stock?

Charles River Laboratories International's stock was sold by a variety of institutional investors in the last quarter, including Channing Capital Management LLC, Hodges Capital Management Inc., Van Berkom & Associates Inc., Pembroke Management LTD, Brown Advisory Inc., Allianz Asset Management GmbH, Neuberger Berman Group LLC and Bank of New York Mellon Corp. Company insiders that have sold Charles River Laboratories International company stock in the last year include Bradley Nixon Scharfe, C Richard Reese, David P Johst, David Ross Smith, Davide Molho, George Massaro, James C Foster, Jason Wesley Scharfe, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Insider Buying and Selling for Charles River Laboratories International.

Who bought Charles River Laboratories International stock? Who is buying Charles River Laboratories International stock?

Charles River Laboratories International's stock was acquired by a variety of institutional investors in the last quarter, including Mackenzie Financial Corp, TimesSquare Capital Management LLC, Putnam FL Investment Management Co., APG Asset Management N.V., Nordea Investment Management AB, Russell Investments Group Ltd., Davidson Kempner Capital Management LP and Cornerstone Capital Management Holdings LLC.. Company insiders that have bought Charles River Laboratories International stock in the last two years include Bradley Nixon Scharfe and Jason Wesley Scharfe. View Insider Buying and Selling for Charles River Laboratories International.

How do I buy Charles River Laboratories International stock?

Shares of Charles River Laboratories International can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Charles River Laboratories International's stock price today?

One share of Charles River Laboratories International stock can currently be purchased for approximately $102.43.

How big of a company is Charles River Laboratories International?

Charles River Laboratories International has a market capitalization of $4.80 billion and generates $1.68 billion in revenue each year. The medical research company earns $154.76 million in net income (profit) each year or $4.09 on an earnings per share basis. Charles River Laboratories International employs 11,000 workers across the globe.

How can I contact Charles River Laboratories International?

Charles River Laboratories International's mailing address is 251 Ballardvale St, WILMINGTON, MA 01887-1096, United States. The medical research company can be reached via phone at +1-781-2226000 or via email at [email protected]


MarketBeat Community Rating for Charles River Laboratories International (NYSE CRL)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  245 (Vote Outperform)
Underperform Votes:  300 (Vote Underperform)
Total Votes:  545
MarketBeat's community ratings are surveys of what our community members think about Charles River Laboratories International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Charles River Laboratories International (NYSE:CRL)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 5 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $106.65 (4.12% upside)

Consensus Price Target History for Charles River Laboratories International (NYSE:CRL)

Price Target History for Charles River Laboratories International (NYSE:CRL)

Analysts' Ratings History for Charles River Laboratories International (NYSE:CRL)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/17/2017SunTrust Banks, Inc.Reiterated RatingBuy$113.00N/AView Rating Details
11/13/2017Robert W. BairdSet Price TargetBuy$117.00N/AView Rating Details
11/10/2017Bank of America CorporationLower Price TargetBuy$117.00 -> $115.00N/AView Rating Details
10/16/2017Credit Suisse GroupReiterated RatingNeutral$95.00 -> $112.00N/AView Rating Details
10/9/2017Jefferies Group LLCBoost Price TargetBuy$120.00 -> $130.00N/AView Rating Details
9/19/2017Royal Bank Of CanadaInitiated CoverageSector Perform -> Sector Perform$110.00MediumView Rating Details
7/19/2017Barclays PLCReiterated RatingHold$102.00LowView Rating Details
6/28/2017Citigroup Inc.Reiterated RatingNeutral$91.00 -> $104.00LowView Rating Details
1/4/2017Evercore ISIUpgradeHold -> Buy$86.50N/AView Rating Details
12/16/2016Goldman Sachs Group, Inc. (The)UpgradeSell -> Neutral$75.00 -> $77.00N/AView Rating Details
5/22/2016KeyCorpReiterated RatingHold$77.00N/AView Rating Details
4/26/2016GabelliInitiated CoverageBuy$96.00N/AView Rating Details
2/11/2016Deutsche Bank AGReiterated RatingHold$85.00 -> $82.00N/AView Rating Details
1/7/2016Wells Fargo & CompanyUpgradeMarket Perform -> OutperformN/AView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for Charles River Laboratories International (NYSE:CRL)

Earnings by Quarter for Charles River Laboratories International (NYSE:CRL)

Earnings History by Quarter for Charles River Laboratories International (NYSE CRL)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018$1.26N/AView Earnings Details
11/9/2017Q3 2017$1.22$1.30$458.93 million$464.23 millionViewN/AView Earnings Details
8/9/2017Q2 2017$1.22$1.29$458.25 million$469.13 millionViewListenView Earnings Details
5/10/2017Q1 2017$1.14$1.29$437.04 million$445.80 millionViewN/AView Earnings Details
2/14/2017Q416$1.11$1.21$441.64 million$466.80 millionViewListenView Earnings Details
11/2/2016Q316$1.13$1.18$291.20 million$425.70 millionViewListenView Earnings Details
8/3/2016Q216$1.10$1.20$425.05 million$434.10 millionViewListenView Earnings Details
5/4/2016Q116$0.90$0.98$354.92 million$354.90 millionViewListenView Earnings Details
2/10/2016Q415$0.94$1.00$349.20 million$353.90 millionViewListenView Earnings Details
11/4/2015Q315$0.94$1.03$340.09 million$349.50 millionViewListenView Earnings Details
7/30/2015Q215$0.97$0.96$338.30 million$339.60 millionViewListenView Earnings Details
4/29/2015Q115$0.82$0.79$324.00 million$320.40 millionViewListenView Earnings Details
2/10/2015Q414$0.71$0.81$318.73 million$329.50 millionViewListenView Earnings Details
10/29/2014Q314$0.80$0.86$326.70 million$327.60 millionViewListenView Earnings Details
8/6/2014Q214$0.82$0.97$327.96 million$341.18 millionViewListenView Earnings Details
4/30/2014Q114$0.74$0.82$302.08 million$299.40 millionViewListenView Earnings Details
2/12/2014Q413$0.68$0.73$289.56 million$289.20 millionViewListenView Earnings Details
10/30/2013Q313$0.70$0.79$290.28 million$292.10 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.71$0.73$293.77 million$294.40 millionViewListenView Earnings Details
5/1/2013Q1 2013$0.71$0.69$294.53 million$291.20 millionViewListenView Earnings Details
2/13/2013Q4 2012$0.60$0.64$280.81 million$280.10 millionViewListenView Earnings Details
10/30/2012$0.62$0.65ViewN/AView Earnings Details
8/7/2012$0.66$0.75ViewN/AView Earnings Details
5/2/2012$0.65$0.70ViewN/AView Earnings Details
2/13/2012$0.56$0.69ViewN/AView Earnings Details
11/1/2011$0.58$0.57ViewN/AView Earnings Details
8/2/2011$0.60$0.70ViewN/AView Earnings Details
5/3/2011$0.55$0.61ViewN/AView Earnings Details
2/8/2011$0.50$0.60ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Charles River Laboratories International (NYSE:CRL)
2017 EPS Consensus Estimate: $4.86
2018 EPS Consensus Estimate: $5.60
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175$1.07$1.16$1.13
Q2 20175$1.21$1.29$1.23
Q3 20175$1.21$1.25$1.23
Q4 20175$1.24$1.33$1.27
Q1 20183$1.30$1.32$1.31
Q2 20183$1.40$1.46$1.44
Q3 20182$1.39$1.42$1.41
Q4 20182$1.38$1.50$1.44
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Charles River Laboratories International (NYSE:CRL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Charles River Laboratories International (NYSE CRL)

Insider Ownership Percentage: 2.20%
Institutional Ownership Percentage: 98.72%
Insider Trades by Quarter for Charles River Laboratories International (NYSE:CRL)
Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Insider Trades by Quarter for Charles River Laboratories International (NYSE CRL)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/10/2017Bradley Nixon ScharfeInsiderSell1,000,000$0.27$270,000.00
10/30/2017Bradley Nixon ScharfeInsiderBuy2,500$0.25$625.00
10/25/2017Bradley Nixon ScharfeInsiderBuy3,000$0.27$810.00
10/19/2017Bradley Nixon ScharfeInsiderBuy2,000$0.29$580.00
10/17/2017Bradley Nixon ScharfeInsiderBuy3,000$0.29$870.00
10/5/2017Davide MolhoInsiderSell6,165$110.00$678,150.00View SEC Filing  
9/5/2017Davide MolhoInsiderSell5,982$107.55$643,364.10View SEC Filing  
8/17/2017William D BarboInsiderSell4,000$99.91$399,640.00View SEC Filing  
8/14/2017David Ross SmithInsiderSell2,552$67.10$171,239.20View SEC Filing  
7/17/2017George MassaroDirectorSell3,830$100.81$386,102.30View SEC Filing  
7/10/2017James C FosterChairmanSell9,516$98.92$941,322.72View SEC Filing  
6/22/2017Davide MolhoInsiderSell10,948$100.00$1,094,800.00View SEC Filing  
6/22/2017James C FosterChairmanSell43,154$100.00$4,315,400.00View SEC Filing  
6/8/2017David Ross SmithInsiderSell945$95.00$89,775.00View SEC Filing  
5/26/2017Davide MolhoInsiderSell10,976$92.84$1,019,011.84View SEC Filing  
5/23/2017Jason Wesley ScharfeDirectorSell10,000$0.31$3,100.00
5/17/2017Jason Wesley ScharfeDirectorSell10,000$0.34$3,400.00
5/12/2017George MassaroDirectorSell1,130$88.30$99,779.00View SEC Filing  
5/11/2017Jason Wesley ScharfeDirectorSell6,000$0.36$2,160.00
5/10/2017Jason Wesley ScharfeDirectorSell9,000$0.36$3,240.00
3/29/2017Jason Wesley ScharfeDirectorSell10,000$0.34$3,400.00
3/16/2017Davide MolhoInsiderSell11,717$90.00$1,054,530.00View SEC Filing  
3/10/2017David P JohstInsiderSell34,593$89.06$3,080,852.58View SEC Filing  
3/6/2017William D BarboInsiderSell1,900$87.90$167,010.00View SEC Filing  
3/3/2017David Ross SmithEVPSell3,890$88.12$342,786.80View SEC Filing  
3/1/2017Robert J BertoliniDirectorSell5,255$87.53$459,970.15View SEC Filing  
2/28/2017James C FosterChairmanSell4,910$87.09$427,611.90View SEC Filing  
2/22/2017James C FosterChairmanSell9,717$87.64$851,597.88View SEC Filing  
2/22/2017Jason Wesley ScharfeDirectorBuy15,000$0.29$4,350.00
2/21/2017Jason Wesley ScharfeDirectorBuy10,000$0.30$3,000.00
2/17/2017Jason Wesley ScharfeDirectorBuy10,000$0.30$3,000.00
2/15/2017Jason Wesley ScharfeDirectorBuy4,500$0.30$1,350.00
1/30/2017David P JohstInsiderSell13,950$78.00$1,088,100.00View SEC Filing  
12/2/2016Stephen D ChubbDirectorSell4,564$71.57$326,645.48View SEC Filing  
11/28/2016C Richard ReeseDirectorSell4,539$71.93$326,490.27View SEC Filing  
8/30/2016Davide MolhoInsiderSell7,877$84.10$662,455.70View SEC Filing  
8/5/2016James C FosterChairmanSell18,351$85.63$1,571,396.13View SEC Filing  
7/29/2016Richard F WallmanDirectorSell7,740$88.00$681,120.00View SEC Filing  
7/1/2016George MassaroDirectorSell3,740$83.09$310,756.60View SEC Filing  
5/24/2016John J CrowleyCAOSell1,913$85.00$162,605.00View SEC Filing  
5/13/2016Richard F WallmanDirectorSell1,970$82.32$162,170.40View SEC Filing  
5/10/2016Richard F WallmanDirectorSell11,990$84.00$1,007,160.00View SEC Filing  
5/9/2016George MassaroDirectorSell985$82.17$80,937.45View SEC Filing  
5/6/2016Richard F WallmanDirectorSell2,720$81.00$220,320.00View SEC Filing  
4/6/2016Davide MolhoVPSell30,667$80.00$2,453,360.00View SEC Filing  
3/2/2016Nancy GillettVPSell7,015$75.00$526,125.00View SEC Filing  
2/29/2016Nancy GillettVPSell3,646$73.50$267,981.00View SEC Filing  
2/25/2016David P JohstVPSell34,075$73.02$2,488,156.50View SEC Filing  
2/24/2016James C FosterCEOSell3,873$70.40$272,659.20View SEC Filing  
2/23/2016George M Milne JrDirectorSell10,440$73.02$762,328.80View SEC Filing  
2/22/2016James C FosterCEOSell9,831$73.12$718,842.72View SEC Filing  
2/12/2016C Richard ReeseDirectorSell4,228$71.48$302,217.44View SEC Filing  
2/12/2016Nancy GillettVPSell6,750$71.90$485,325.00View SEC Filing  
2/1/2016Stephen D ChubbDirectorSell2,000$74.76$149,520.00View SEC Filing  
12/17/2015George MassaroDirectorSell7,740$80.00$619,200.00View SEC Filing  
12/17/2015Thomas F. AckermaninsiderSell10,000$80.00$800,000.00View SEC Filing  
11/19/2015Thomas F. AckermaninsiderSell10,000$75.00$750,000.00View SEC Filing  
11/4/2015Thomas F. AckermaninsiderSell21,612$70.01$1,513,056.12View SEC Filing  
11/2/2015Stephen D ChubbDirectorSell2,000$66.57$133,140.00View SEC Filing  
8/17/2015Thomas F AckermanInsiderSell5,000$75.53$377,650.00View SEC Filing  
5/15/2015Thomas F AckermanCFOSell3,900$70.51$274,989.00View SEC Filing  
5/7/2015George MassaroDirectorSell1,360$70.21$95,485.60View SEC Filing  
3/3/2015Stephen D ChubbDirectorSell2,000$75.52$151,040.00View SEC Filing  
3/2/2015Deborah Turner KochevarDirectorSell2,600$76.59$199,134.00View SEC Filing  
3/2/2015James C FosterCEOSell2,036$76.93$156,629.48View SEC Filing  
3/2/2015Nancy GillettVPSell4,379$76.72$335,956.88View SEC Filing  
2/27/2015Nancy GillettVPSell2,772$76.95$213,305.40View SEC Filing  
2/25/2015James C FosterCEOSell4,621$75.96$351,011.16View SEC Filing  
2/25/2015Nancy GillettVPSell5,015$76.12$381,741.80View SEC Filing  
2/24/2015James C FosterCEOSell4,800$75.70$363,360.00View SEC Filing  
2/24/2015Jorg GellerVPSell12,061$76.17$918,686.37View SEC Filing  
2/23/2015James C FosterCEOSell8,423$76.56$644,864.88View SEC Filing  
2/23/2015Jorg GellerVPSell7,041$76.59$539,270.19View SEC Filing  
2/20/2015George M Milne JrDirectorSell6,000$75.87$455,220.00View SEC Filing  
2/19/2015James C FosterCEOSell9,671$75.00$725,325.00View SEC Filing  
2/18/2015Stephen D ChubbDirectorSell5,011$73.97$370,663.67View SEC Filing  
2/17/2015Jorg GellerVPSell14,430$73.54$1,061,182.20View SEC Filing  
2/17/2015Thomas F AckermanCFOSell4,400$73.50$323,400.00View SEC Filing  
2/13/2015Davide MolhoVPSell19,075$74.00$1,411,550.00View SEC Filing  
2/12/2015Jorg GellerVPSell8,458$73.68$623,185.44View SEC Filing  
1/26/2015Thomas F AckermanCFOSell10,000$70.00$700,000.00View SEC Filing  
1/8/2015David P JohstVPSell4,737$67.00$317,379.00View SEC Filing  
1/7/2015David P JohstVPSell26,100$65.00$1,696,500.00View SEC Filing  
12/1/2014Stephen D ChubbDirectorSell2,000$64.44$128,880.00View SEC Filing  
11/28/2014David P JohstVPSell6,982$65.34$456,203.88View SEC Filing  
11/17/2014Thomas F AckermanCFOSell10,000$63.70$637,000.00View SEC Filing  
11/14/2014Jorg GellerVPSell5,610$63.57$356,627.70View SEC Filing  
11/6/2014C Richard ReeseDirectorSell5,849$63.39$370,768.11View SEC Filing  
11/4/2014John J CrowleyCAOSell1,000$64.00$64,000.00View SEC Filing  
11/3/2014Davide MolhoVPSell16,402$64.54$1,058,585.08View SEC Filing  
11/3/2014George MassaroDirectorSell16,710$65.00$1,086,150.00View SEC Filing  
11/3/2014Thomas F AckermanCFOSell36,100$65.00$2,346,500.00View SEC Filing  
10/30/2014Nancy GillettVPSell1,069$65.00$69,485.00View SEC Filing  
10/28/2014David P JohstVPSell74,780$64.00$4,785,920.00View SEC Filing  
10/3/2014James C FosterCEOSell136,647$62.00$8,472,114.00View SEC Filing  
9/29/2014Thomas F AckermanCFOSell5,000$60.00$300,000.00View SEC Filing  
9/4/2014Davide MolhoVPSell4,900$61.34$300,566.00View SEC Filing  
9/2/2014Stephen D ChubbDirectorSell2,000$59.18$118,360.00View SEC Filing  
8/26/2014George MassaroDirectorSell10,440$60.00$626,400.00View SEC Filing  
8/18/2014Thomas F AckermanCFOSell23,156$59.25$1,371,993.00View SEC Filing  
8/12/2014Richard F WallmanDirectorSell3,240$58.20$188,568.00View SEC Filing  
6/2/2014Stephen D ChubbDirectorSell2,000$52.93$105,860.00View SEC Filing  
5/22/2014Deborah Turner KochevarDirectorSell3,100$53.30$165,230.00View SEC Filing  
5/8/2014George MassaroDirectorSell1,620$52.70$85,374.00View SEC Filing  
5/5/2014Thomas AckermanCFOSell5,430$50.76$275,626.80View SEC Filing  
3/7/2014Nancy GillettVPSell10,110$58.36$590,019.60View SEC Filing  
3/4/2014Nancy GillettVPSell13,650$58.98$805,077.00View SEC Filing  
3/3/2014Stephen ChubbDirectorSell2,000$58.70$117,400.00View SEC Filing  
2/28/2014Jorg GellerVPSell7,486$59.41$444,743.26View SEC Filing  
2/27/2014Nancy GillettVPSell4,000$60.00$240,000.00View SEC Filing  
2/25/2014Jorg GellerVPSell3,188$58.49$186,466.12View SEC Filing  
2/20/2014Nancy GillettVPSell4,000$58.96$235,840.00View SEC Filing  
2/19/2014Stephen ChubbDirectorSell5,198$58.35$303,303.30View SEC Filing  
2/18/2014Thomas AckermanCFOSell14,000$58.05$812,700.00View SEC Filing  
1/13/2014David JohstVPSell19,750$58.00$1,145,500.00View SEC Filing  
1/7/2014George MassaroDirectorSell5,750$54.00$310,500.00View SEC Filing  
12/20/2013Thomas AckermanCFOSell5,000$52.72$263,600.00View SEC Filing  
12/4/2013Jorg GellerVPSell7,200$51.93$373,896.00View SEC Filing  
12/2/2013Stephen ChubbDirectorSell2,000$51.92$103,840.00View SEC Filing  
9/16/2013George MassaroDirectorSell5,958$47.38$282,290.04View SEC Filing  
9/9/2013James C FosterCEOSell174,479$47.00$8,200,513.00View SEC Filing  
9/4/2013Thomas F AckermanCFOSell6,100$46.13$281,393.00View SEC Filing  
9/3/2013Stephen ChubbDirectorSell2,000$46.49$92,980.00View SEC Filing  
8/29/2013James FosterCEOSell40,983$47.00$1,926,201.00View SEC Filing  
8/22/2013Davide MolhoVPSell6,500$47.93$311,545.00View SEC Filing  
8/20/2013Stephen ChubbDirectorSell4,000$47.46$189,840.00View SEC Filing  
8/5/2013Jorg GellerVPSell3,025$46.38$140,299.50View SEC Filing  
8/5/2013Richard WallmanDirectorSell1,500$45.95$68,925.00View SEC Filing  
8/2/2013Davide MolhoVPSell4,100$45.89$188,149.00View SEC Filing  
8/2/2013Deborah Turner KochevarDirectorSell4,447$46.02$204,650.94View SEC Filing  
8/2/2013Thomas AckermanCFOSell26,250$46.03$1,208,287.50View SEC Filing  
6/3/2013Thomas F AckermanCFOSell4,000$42.40$169,600.00View SEC Filing  
5/14/2013James C FosterCEOSell113,810$45.00$5,121,450.00View SEC Filing  
5/10/2013George MassaroDirectorSell2,020$44.09$89,061.80View SEC Filing  
3/13/2013David P JohstVPSell17,038$45.00$766,710.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Charles River Laboratories International (NYSE CRL)

Source:
DateHeadline
ETFs with exposure to Charles River Laboratories International, Inc. : November 20, 2017ETFs with exposure to Charles River Laboratories International, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 6:35 PM
SunTrust Banks Comments on Charles River Laboratories International, Inc.s FY2018 Earnings (CRL)SunTrust Banks Comments on Charles River Laboratories International, Inc.'s FY2018 Earnings (CRL)
www.americanbankingnews.com - November 20 at 9:22 AM
Charles River Laboratories (CRL) Presents At Jefferies 2017 London Healthcare Conference - SlideshowCharles River Laboratories (CRL) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
seekingalpha.com - November 17 at 11:47 PM
Charles River Laboratories International, Inc. (CRL) Receives "Buy" Rating from SunTrust Banks, Inc.Charles River Laboratories International, Inc. (CRL) Receives "Buy" Rating from SunTrust Banks, Inc.
www.americanbankingnews.com - November 17 at 11:26 PM
Q1 2018 EPS Estimates for Charles River Laboratories International, Inc. Reduced by Analyst (CRL)Q1 2018 EPS Estimates for Charles River Laboratories International, Inc. Reduced by Analyst (CRL)
www.americanbankingnews.com - November 17 at 11:00 PM
SunTrust Banks Comments on Charles River Laboratories International, Inc.s FY2017 Earnings (CRL)SunTrust Banks Comments on Charles River Laboratories International, Inc.'s FY2017 Earnings (CRL)
www.americanbankingnews.com - November 17 at 9:21 PM
Charles River Laboratories International, Inc. :CRL-US: Earnings Analysis: Q3, 2017 By the Numbers : November 15, 2017Charles River Laboratories International, Inc. :CRL-US: Earnings Analysis: Q3, 2017 By the Numbers : November 15, 2017
finance.yahoo.com - November 17 at 1:45 PM
Charles River Laboratories to close Frederick research facility, lay off 57 workersCharles River Laboratories to close Frederick research facility, lay off 57 workers
www.bizjournals.com - November 14 at 5:56 PM
Earnings Review and Free Research Report: Labcorp’s Revenue Jumped 9.5%; Raised Outlook for 2017Earnings Review and Free Research Report: Labcorp’s Revenue Jumped 9.5%; Raised Outlook for 2017
finance.yahoo.com - November 14 at 5:56 PM
Charles River Laboratories International, Inc. (CRL) Forecasted to Post FY2017 Earnings of $5.14 Per ShareCharles River Laboratories International, Inc. (CRL) Forecasted to Post FY2017 Earnings of $5.14 Per Share
www.americanbankingnews.com - November 14 at 9:04 AM
Charles River Laboratories International, Inc. – Value Analysis (NYSE:CRL) : November 13, 2017Charles River Laboratories International, Inc. – Value Analysis (NYSE:CRL) : November 13, 2017
finance.yahoo.com - November 13 at 9:19 PM
Charles River Laboratories International, Inc. (CRL) Lowered to "Hold" at Zacks Investment ResearchCharles River Laboratories International, Inc. (CRL) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - November 13 at 8:30 PM
Robert W. Baird Reaffirms Buy Rating for Charles River Laboratories International, Inc. (CRL)Robert W. Baird Reaffirms Buy Rating for Charles River Laboratories International, Inc. (CRL)
www.americanbankingnews.com - November 13 at 7:50 PM
Insider Selling: Charles River Laboratories International, Inc. (CRL) Insider Sells 1,000,000 Shares of StockInsider Selling: Charles River Laboratories International, Inc. (CRL) Insider Sells 1,000,000 Shares of Stock
www.americanbankingnews.com - November 13 at 6:04 PM
Charles River Laboratories International, Inc. (CRL) to Post FY2018 Earnings of $5.45 Per Share, Gabelli ForecastsCharles River Laboratories International, Inc. (CRL) to Post FY2018 Earnings of $5.45 Per Share, Gabelli Forecasts
www.americanbankingnews.com - November 13 at 8:58 AM
FY2017 EPS Estimates for Charles River Laboratories International, Inc. Lifted by William Blair (CRL)FY2017 EPS Estimates for Charles River Laboratories International, Inc. Lifted by William Blair (CRL)
www.americanbankingnews.com - November 13 at 3:56 AM
Charles River Laboratories International, Inc. (CRL) to Post Q1 2018 Earnings of $1.34 Per Share, William Blair ForecastsCharles River Laboratories International, Inc. (CRL) to Post Q1 2018 Earnings of $1.34 Per Share, William Blair Forecasts
www.americanbankingnews.com - November 12 at 6:30 AM
$477.46 Million in Sales Expected for Charles River Laboratories International, Inc. (CRL) This Quarter$477.46 Million in Sales Expected for Charles River Laboratories International, Inc. (CRL) This Quarter
www.americanbankingnews.com - November 12 at 3:10 AM
Charles River Laboratories International, Inc. (CRL) Price Target Cut to $115.00 by Analysts at Bank of America CorporationCharles River Laboratories International, Inc. (CRL) Price Target Cut to $115.00 by Analysts at Bank of America Corporation
www.americanbankingnews.com - November 11 at 8:24 PM
Charles River Laboratories International, Inc. (CRL) Stock Rating Lowered by ValuEngineCharles River Laboratories International, Inc. (CRL) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - November 11 at 7:00 PM
$1.30 EPS Expected for Charles River Laboratories International, Inc. (CRL) This Quarter$1.30 EPS Expected for Charles River Laboratories International, Inc. (CRL) This Quarter
www.americanbankingnews.com - November 10 at 7:06 PM
Charles River Laboratories International, Inc. breached its 50 day moving average in a Bearish Manner : CRL-US : November 10, 2017Charles River Laboratories International, Inc. breached its 50 day moving average in a Bearish Manner : CRL-US : November 10, 2017
finance.yahoo.com - November 10 at 5:25 PM
Charles River Laboratories International Enters Oversold Territory (CRL)Charles River Laboratories International Enters Oversold Territory (CRL)
www.nasdaq.com - November 10 at 6:12 AM
Charles River Laboratories International (CRL) Q3 2017 Results - Earnings Call TranscriptCharles River Laboratories International (CRL) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 10 at 6:12 AM
Charles River Laboratories Announces Third-Quarter 2017 Results from Continuing OperationsCharles River Laboratories Announces Third-Quarter 2017 Results from Continuing Operations
finance.yahoo.com - November 10 at 6:12 AM
Charles River tops Street 3Q forecastsCharles River tops Street 3Q forecasts
finance.yahoo.com - November 10 at 6:12 AM
What Should You Know About Charles River Laboratories International Inc’s (CRL) Future?What Should You Know About Charles River Laboratories International Inc’s (CRL) Future?
finance.yahoo.com - November 10 at 6:12 AM
ETFs with exposure to Charles River Laboratories International, Inc. : November 9, 2017ETFs with exposure to Charles River Laboratories International, Inc. : November 9, 2017
finance.yahoo.com - November 10 at 6:12 AM
Edited Transcript of CRL earnings conference call or presentation 9-Nov-17 1:30pm GMTEdited Transcript of CRL earnings conference call or presentation 9-Nov-17 1:30pm GMT
finance.yahoo.com - November 10 at 6:12 AM
Charles River Laboratories International, Inc. (CRL) Posts Quarterly  Earnings Results, Beats Expectations By $0.08 EPSCharles River Laboratories International, Inc. (CRL) Posts Quarterly Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - November 9 at 3:46 PM
Charles River Laboratories International, Inc. (CRL) Issues FY17 Earnings GuidanceCharles River Laboratories International, Inc. (CRL) Issues FY17 Earnings Guidance
www.americanbankingnews.com - November 9 at 9:27 AM
Why Earnings Season Could Be Great for Charles River Laboratories (CRL)Why Earnings Season Could Be Great for Charles River Laboratories (CRL)
finance.yahoo.com - November 8 at 10:40 PM
Charles River Laboratories International, Inc. (CRL) Receives Average Recommendation of "Buy" from AnalystsCharles River Laboratories International, Inc. (CRL) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 5 at 9:32 AM
Charles River Laboratories Presents Newly Expanded Capabilities at Neuroscience 2017Charles River Laboratories Presents Newly Expanded Capabilities at Neuroscience 2017
finance.yahoo.com - November 1 at 6:24 PM
Charles River Laboratories International, Inc. (CRL) Scheduled to Post Quarterly Earnings on WednesdayCharles River Laboratories International, Inc. (CRL) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 7:46 AM
Https://insphero.com/Https://insphero.com/
www.thestreet.com - October 28 at 10:52 PM
BRIEF-Charles River announces expansion of in vitro oncology servicesBRIEF-Charles River announces expansion of in vitro oncology services
www.reuters.com - October 28 at 12:02 AM
First Week of CRL May 2018 Options TradingFirst Week of CRL May 2018 Options Trading
www.nasdaq.com - October 28 at 12:02 AM
Charles River Announces Expansion of In Vitro Oncology ServicesCharles River Announces Expansion of In Vitro Oncology Services
finance.yahoo.com - October 26 at 2:48 PM
Charles River Laboratories International, Inc. (CRL) Lifted to Buy at Zacks Investment ResearchCharles River Laboratories International, Inc. (CRL) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - October 24 at 8:00 PM
$459.42 Million in Sales Expected for Charles River Laboratories International, Inc. (CRL) This Quarter$459.42 Million in Sales Expected for Charles River Laboratories International, Inc. (CRL) This Quarter
www.americanbankingnews.com - October 23 at 1:22 AM
Charles River Laboratories International, Inc. (CRL) Expected to Announce Earnings of $1.22 Per ShareCharles River Laboratories International, Inc. (CRL) Expected to Announce Earnings of $1.22 Per Share
www.americanbankingnews.com - October 22 at 12:24 AM
Financial Survey: Charles River Laboratories International (CRL) and Its RivalsFinancial Survey: Charles River Laboratories International (CRL) and Its Rivals
www.americanbankingnews.com - October 18 at 4:26 PM
Critical Analysis: OncoSec Medical (ONCS) and Charles River Laboratories International (CRL)Critical Analysis: OncoSec Medical (ONCS) and Charles River Laboratories International (CRL)
www.americanbankingnews.com - October 17 at 10:24 PM
Charles River Laboratories International, Inc. (CRL) Receives Neutral Rating from Credit Suisse GroupCharles River Laboratories International, Inc. (CRL) Receives Neutral Rating from Credit Suisse Group
www.americanbankingnews.com - October 16 at 10:10 AM
Charles River Laboratories Changes the Date of Its Third-Quarter 2017 Earnings Release and Conference CallCharles River Laboratories Changes the Date of Its Third-Quarter 2017 Earnings Release and Conference Call
finance.yahoo.com - October 12 at 6:20 PM
Charles River Laboratories Schedules Third-Quarter 2017 Earnings Release and Conference CallCharles River Laboratories Schedules Third-Quarter 2017 Earnings Release and Conference Call
finance.yahoo.com - October 11 at 7:01 PM
Charles River Laboratories International, Inc. (CRL) Given Consensus Rating of "Buy" by AnalystsCharles River Laboratories International, Inc. (CRL) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - October 11 at 10:58 AM
Charles River Laboratories International (CRL) vs. Heron Therapeutics (HRTX) Financial AnalysisCharles River Laboratories International (CRL) vs. Heron Therapeutics (HRTX) Financial Analysis
www.americanbankingnews.com - October 9 at 10:26 PM
Charles River Laboratories International, Inc. (CRL) Price Target Raised to $130.00Charles River Laboratories International, Inc. (CRL) Price Target Raised to $130.00
www.americanbankingnews.com - October 9 at 10:16 PM

Social Media

Financials

Chart

Charles River Laboratories International (NYSE CRL) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.